_________________________________ 4. NEWS: TB/HIV funding request to the Global Fund Tanzania’s yields three grants Funding request identifies vulnerable groups for TB Kataisee Richardson 6 March 2018 Mainland Tanzania submitted a funding request for its HIV and TB components that resulted in the Global Fund Board approving three grants, including a TB/HIV grant to a civil society principal recipient (PR) AMREF Health Africa. The Ministry of Finance and Planning –– (MOFP) was awarded an HIV grant and a TB grant. Tanzania is one of the countries in sub-Saharan Africa most heavily impacted by HIV and TB. The HIV prevalence among adults aged 15–49 was estimated at 5.3% in 2012, which nevertheless represents a steady decline from 7% in 2003. HIV prevalence is highest among key populations. These include men who have sex with men (MSM), people who inject drugs (PWID), and sex workers, whose rates are estimated at 25%, 36% and 26%, respectively. Data suggests that HIV infection rates begin to rise much earlier in girls than boys, creating a need to provide age-tailored prevention services to adolescent girls. Significant strides have been made to address vertical transmission of HIV with near universal antiretroviral therapy (ART) coverage of HIV-infected pregnant women. Tanzania ranks 6th globally in terms of its TB and TB/HIV burdens. The prevalence of TB is estimated by the World Health Organization (WHO) to be 528 per 100,000, with treatment coverage of only 37%, making it particularly critical for the National TB Program to identify and treat the missing TB cases. allocation for 2017–2019 was $579.6 million. The indicative breakdown of the Tanzania’s allocation was as follows: HIV $408.5 million –– TB $25.8 million –– Malaria $145.3 million –– Total $579.6 million –– After Tanzania moved $43.5 million from HIV to malaria to cover resilient and sustainable systems for health (RSSH) activities, and made additional minor adjustments, the final approved program split was as follows: HIV $364.3 million –– TB $26.5 million –– Malaria $188.8 million –– Total $579.6 million ––
_________________________________ 4. NEWS: Tanzania’s TB/HIV funding request to the Global Fund yields three grants Funding request identifies vulnerable groups for TB Kataisee Richardson 6 March 2018 Mainland Tanzania submitted a funding request for its HIV and TB components that resulted in the Global Fund Board approving three grants, including a TB/HIV grant to a civil society principal recipient (PR) –– AMREF Health Africa. The Ministry of Finance and Planning (MOFP) was awarded an HIV grant and a TB grant. Tanzania is one of the countries in sub-Saharan Africa most heavily impacted by HIV and TB. The HIV prevalence among adults aged 15–49 was estimated at 5.3% in 2012, which nevertheless represents a steady decline from 7% in 2003. HIV prevalence is highest among key populations. These include men who have sex with men (MSM), people who inject drugs (PWID), and sex workers, whose rates are estimated at 25%, 36% and 26%, respectively. Data suggests that HIV infection rates begin to rise much earlier in girls than boys, creating a need to provide age-tailored prevention services to adolescent girls. Significant strides have been made to address vertical transmission of HIV with near universal antiretroviral therapy (ART) coverage of HIV-infected pregnant women. Tanzania ranks 6th globally in terms of its TB and TB/HIV burdens. The prevalence of TB is estimated by the World Health Organization (WHO) to be 528 per 100,000, with treatment coverage of only 37%, making it particularly critical for the National TB Program to identify and treat the missing TB cases. Tanzania’s allocation for 2017–2019 was $579.6 million. The indicative breakdown of the allocation was as follows: HIV –– $408.5 million TB –– $25.8 million Malaria –– $145.3 million Total –– $579.6 million After Tanzania moved $43.5 million from HIV to malaria to cover resilient and sustainable systems for health (RSSH) activities, and made additional minor adjustments, the final approved program split was as follows: HIV –– $364.3 million TB –– $26.5 million Malaria –– $188.8 million Total –– $579.6 million
GFO-Issue-332.docx